AU2010229142A1 - P2X3, receptor antagonists for treatment of pain - Google Patents

P2X3, receptor antagonists for treatment of pain Download PDF

Info

Publication number
AU2010229142A1
AU2010229142A1 AU2010229142A AU2010229142A AU2010229142A1 AU 2010229142 A1 AU2010229142 A1 AU 2010229142A1 AU 2010229142 A AU2010229142 A AU 2010229142A AU 2010229142 A AU2010229142 A AU 2010229142A AU 2010229142 A1 AU2010229142 A1 AU 2010229142A1
Authority
AU
Australia
Prior art keywords
chr
alkyl
cycloalkyl
mmol
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010229142A
Other languages
English (en)
Inventor
Christopher S. Burgey
Zhengwu J. Deng
John J. Lim
Diem N. Nguyen
Ashley Nomland
Daniel V. Paone
Craig M. Potteiger
Carolyn Segerdell
Shaun R. Stauffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2010229142A1 publication Critical patent/AU2010229142A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK SHARP & DOHME CORP.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010229142A 2009-03-23 2010-03-15 P2X3, receptor antagonists for treatment of pain Abandoned AU2010229142A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21084509P 2009-03-23 2009-03-23
US61/210,845 2009-03-23
PCT/US2010/027286 WO2010111058A1 (en) 2009-03-23 2010-03-15 P2x3, receptor antagonists for treatment of pain

Publications (1)

Publication Number Publication Date
AU2010229142A1 true AU2010229142A1 (en) 2011-10-13

Family

ID=42781385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010229142A Abandoned AU2010229142A1 (en) 2009-03-23 2010-03-15 P2X3, receptor antagonists for treatment of pain

Country Status (6)

Country Link
US (1) US9238647B2 (enExample)
EP (1) EP2410857B1 (enExample)
JP (1) JP2012521428A (enExample)
AU (1) AU2010229142A1 (enExample)
CA (1) CA2755680A1 (enExample)
WO (1) WO2010111058A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5539235B2 (ja) 2008-02-29 2014-07-02 エボテック・アーゲー アミド化合物、組成物およびそれらの使用
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
US20100273805A1 (en) * 2009-04-23 2010-10-28 Astrazeneca Ab Sulphide bridged derivatives as modulators of mglur5 733
WO2010149634A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists
ES2552455T3 (es) * 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9012448B2 (en) * 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
AU2012254082B2 (en) * 2011-02-25 2016-12-08 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
KR102120513B1 (ko) * 2013-01-31 2020-06-08 네오메드 인스티튜트 이미다조피리딘 화합물 및 이의 용도
WO2015095128A1 (en) 2013-12-16 2015-06-25 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
EP2905282A1 (en) * 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
EP3188731B1 (en) 2014-09-05 2019-04-03 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2016036633A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
JPWO2016088838A1 (ja) * 2014-12-04 2017-09-14 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
WO2017209267A1 (ja) * 2016-06-03 2017-12-07 塩野義製薬株式会社 プリン誘導体
KR20190085035A (ko) 2016-11-18 2019-07-17 머크 샤프 앤드 돔 코포레이션 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인돌 유도체
JP2020502058A (ja) 2016-11-18 2020-01-23 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ジアシルグリセリドｏ−アシルトランスフェラーゼ２の阻害薬として有用なインダゾール誘導体
CA3055509A1 (en) * 2017-03-15 2018-09-20 Sumitomo Dainippon Pharma Co., Ltd. Novel benzimidazolone compound and pharmaceutical use thereof
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
EP3746444B1 (en) 2018-01-31 2023-09-27 Janssen Sciences Ireland Unlimited Company Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
AU2019260109B2 (en) 2018-04-23 2023-07-13 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
EP3971183A4 (en) * 2019-06-19 2022-08-10 LG Chem, Ltd. Method for producing indole or indazole compound
US20230101612A1 (en) * 2020-02-14 2023-03-30 Bellus Health Cough Inc. Preparation of a p2x3 antagonist
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
CN115322143B (zh) * 2022-07-21 2023-07-14 安徽德诺医药股份有限公司 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法
EP4638420A1 (en) * 2022-12-20 2025-10-29 Exelixis, Inc. Compounds that inhibit pkmyt1

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
IL141724A0 (en) * 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
HUP0202757A3 (en) 1999-08-19 2006-03-28 Nps Pharmaceuticals Inc Salt L Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists
CA2450555A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
EP1711498A2 (en) * 2004-01-26 2006-10-18 Altana Pharma AG 1,2,4-triazolo¬1,5-a|pyridines as gastric acid secretion inhibitors
WO2007010553A2 (en) 2005-03-24 2007-01-25 Arrow Coated Products Ltd Combined multi-layered water soluble film and process for producing the same
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
CN101203220A (zh) 2005-06-28 2008-06-18 阿斯利康(瑞典)有限公司 新用途
ATE537169T1 (de) * 2005-08-15 2011-12-15 Hoffmann La Roche Piperidin- und piperazinderivate als p2x3- antagonisten
MX2008002733A (es) 2005-09-01 2008-03-26 Hoffmann La Roche Diaminopirimidinas como moduladores p2x3 y p2x2/3.
CA2624379A1 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Nucleic acids encoding a functional mammalian purinoreceptor, p2x3, methods of production and use thereof
JP2009514894A (ja) * 2005-11-07 2009-04-09 バーテックス ファーマシューティカルズ インコーポレイテッド ジャイレース阻害剤としてのベンズイミダゾール誘導体
WO2007069053A1 (en) * 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007086080A2 (en) * 2006-01-30 2007-08-02 Glenmark Pharmaceuticals Limited NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2008000645A1 (en) 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Tetrazole-substituted arylamides
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
US7563797B2 (en) * 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
US20100298314A1 (en) * 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
EP2120938A4 (en) * 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
WO2009058298A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
ES2553412T3 (es) 2007-10-31 2015-12-09 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
AU2009309019B2 (en) 2008-10-31 2014-11-13 Merck Sharp & Dohme Llc P2X3, receptor antagonists for treatment of pain
WO2010059836A1 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010149634A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists

Also Published As

Publication number Publication date
US9238647B2 (en) 2016-01-19
CA2755680A1 (en) 2010-09-30
US20120064181A1 (en) 2012-03-15
EP2410857A4 (en) 2012-10-31
WO2010111058A1 (en) 2010-09-30
EP2410857B1 (en) 2014-01-29
JP2012521428A (ja) 2012-09-13
EP2410857A1 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
EP2410857B1 (en) P2x3, receptor antagonists for treatment of pain
AU2010229144B2 (en) P2X3, receptor antagonists for treatment of pain
EP2358371B1 (en) P2x3, receptor antagonists for treatment of pain
AU2008319308B2 (en) P2X3, receptor antagonists for treatment of pain
EP2410858B1 (en) P2x3 receptor antagonists for treatment of pain
EP2215048B1 (en) P2x3 receptor antagonists for treatment of pain
JP5099005B2 (ja) ヘテロ化合物
JP2017505322A (ja) 化合物の組成物およびその使用

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application